1 ratings / 5 average

Advances in Multiple Sclerosis Therapy: New Oral Disease-Modifying Agents

Andreas Lutterotti, MD and Thomas Berger, MD, MSc

For the past 15 years, standard disease-modifying therapies (DMTs) for multiple sclerosis (MS) have been available only as injections, which has limited adherence for many patients. Several new drugs, including monoclonal antibodies and orally administered agents, are currently being studied in MS. As well as having a novel mechanism of action, oral drugs hold the promise of improving patient compliance and adherence to therapy.

Return to top

RELATED ARTICLES

The Role of B Cells in Multiple Sclerosis: Experimental and Clinical Aspects
Til Menge, MD, Gerd Meyer zu Hörste, MD, and Bernd C Kieseier, MD
CML Multiple Sclerosis
Pharmacogenomics in Multiple Sclerosis
Manuel Comabella, MD and Xavier Montalban, MD
CML Multiple Sclerosis
The Role of MRI as a Predictive Marker for Disease Progression Measured by the Expanded Disability Status Scale
Antonia Ceccarelli, MD, Domenico Caputo, MD, and Marco Rovaris, MD
CML Multiple Sclerosis
Optical Coherence Tomography as a Marker of Axonal Damage in Multiple Sclerosis
Shiv Saidha, MRCPI, Christopher Eckstein, MD, and John N Ratchford, MD
CML Multiple Sclerosis

LATEST ARTICLES